The ALDH inhibitor disulfiram, which has been trialled clinically in GBM patients with unmethylated MGMT because of its MGMT inhibitory role71, may be more effective or have additional effects on patients with ALDH3B1-specific deregulation. This evidence concerns the gene MGMT and glioblastoma.